

About the AMR Accelerator

The Innovative Medicines Initiative (IMI), funded by the European Union and the European pharmaceutical industry, responded to the challenge of antimicrobial resistance (AMR) and launched the AMR Accelerator in 2019. With a total budget of 489 M €, 98 partners from large pharmaceutical companies, small and medium-sized enterprises, not-for-profit organisations and the public sector in nine consortia are working together. The aim is to advance a broad, unparalleled portfolio of programmes that target Gram-negative bacteria, *Mycobacterium tuberculosis* and non-tuberculous mycobacteria (NTM).

The AMR Accelerator as a whole has the ambitious goal to deliver 10 new preclinical candidates and 5 Phase II-ready assets by 2025.

The AMR Accelerator Portfolio

98		489		9		13+				
Participants		M€ Budget		Projects		Programmes in the Portfolio				
Last update 08/2022			Novelty		Development Stage					
AMR Accelerator Project	Asset Owner	Programme	New Class	New MoA	Discovery	(Pre)-Hit to Lead	Lead to Candidate	Candidate to Phase I	Phase I	
GNA NDW €31.4 m	EVOTEC	Corramycin	✓	✓			➡			
	NOSOPHARM	NOSD-502	✓	✓				➡		
		NOSD-26	✓	✓			➡			
TRIC-TB €8.3 m	BioVersys and GSK	Boosting Ethionamide	✓	✓					➡	
AB-Direct €3.7 m	GSK	Bepotidacin tissue distribution	✓	✓					➡	
ERA4TB €207 m		ERA4TB-01	✓	✓					➡	
		ERA4TB-02	✓	✓			➡			
		ERA4TB-03								➡
		ERA4TB-04	✓	✓			➡			
		ERA4TB-06	✓	✓			➡			
RespiriTB & NTM €9 m (-TB) €8 m (-NTM)	JANSSEN	JUNJ901							➡	
		RespiriTB	✓	✓	➡					
		RespiriNTM				➡				
UNITE4TB €185 m	TBA									
Accelerating scientific discoveries in the AMR field										
COMBINE €25 m		Providing learnings derived from shared vaccine and/or antibacterial clinical trial data and improving understanding of variability and translatability of animal models of bacterial infection.								
PrIMAVeRa €9.25 m		Developing a decision-making tool accessing health and economic outcomes of vaccines on the reduction of AMR.								

About COMBINE

At the core of the Accelerator is the COMBINE project, a 'Capability Building Network', which coordinates cross-project tasks, but also has its own scientific aims (e.g., to optimise the design of clinical trials and improve animal models used in AMR research) in order to support all Accelerator projects in achieving their goals.

Part of COMBINE's efforts is to promote awareness of the Accelerator projects' activities and results, support outreach activities and establish contacts with other initiatives in the field via targeted networking

Disclaimer

This factsheet reflects the authors' view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

www.amr-accelerator.eu
info@amr-accelerator.eu

AMR ACCELERATOR PARTNERS:

ARES GENETICS GMBH | ASCLEPIA OUTSOURCING SOLUTIONS | BEAM ALLIANCE | BILL & MELINDA GATES FOUNDATION | BIODASTER | BIOCOM | BIOVERSUS | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS | CHU DE POITIERS | CIM-SANT PAU | CLINICAL STUDIES SWEDEN FORUM SOUTH | CONSIGLIO NAZIONALE DELLE RICERCHE | C-PATH | DANMARKS TEKNISKE UNIVERSITET | DZIF | EBERHARD KARLS UNIVERSITÄT TÜBINGEN | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE | ERASMUS MC UNIVERSITY | EUROPEAN LUNG FOUNDATION | EUROPEAN LUNG FOUNDATION EUROPÉ | EUROPEAN RESPIRATORY SOCIETY | EUROPEAN VACCINE INITIATIVE | EVOTEC | FFUND BV | FORSCHUNGSZENTRUM BORSTEL | FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS | FOUNDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS | FRAUNHOFER GESELLSCHAFT | GRITSYSTEMS AS | GSK BIOLOGICALS SA | GSK INVESTIGACION Y DESARROLLO SL | GSK RESEARCH AND DEVELOPMENT LTD | HELMHOLTZ CENTRE FOR INFECTION RESEARCH | HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH | HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNO KLINIKOS | IDIPAZ | IDMIT | IMABIOTECH | INSERM | INSTITUTE OF HEALTH CARLOS III | INSTITUTE PASTEUR | INSTITUTE PASTEUR DE LILLE FOUNDATION | IRD | ISPU | JANSSEN PHARMACEUTICA | JANSSEN VACCINES & PREVENTION B.V. | KLINIKUM DER UNIVERSITÄT MÜNCHEN | KNCV | LEIDS UNIVERSITAIR MEDISCH CENTRUM | LIFE SCIENCE NETWORK GMBH | LIQS | LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN | LYGATURE | MEDICAL UNIVERSITY OF VIENNA | MITOLOGICS | NHS | NICE | NIOSOPHARM | OTSUKA NOVEL PRODUCTS GMBH | PEI | PFIZER | PUBLIC HEALTH ENGLAND | QPS NETHERLANDS | SGIENSAND | SERVICIO ANDALUZ DE SALUD | SSI | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | SYNAPSE RESEARCH MANAGEMENT PARTNERS | TASK FOUNDATION NPC | TB ALLIANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS | TUBERCULOSIS NETWORK EUROPEAN TRIALS GROUP EV | UMC UTRECHT | UNIVERSIDAD CARLOS III MADRID | UNIVERSITÄT HAMBURG | UNIVERSITÀ DEGLI STUDI DI MILANO | UNIVERSITÀ VITA-SALUTE SAN RAFFAELE | UNIVERSITÉ DE POITIERS | UNIVERSITÉ GRENoble ALPES | UNIVERSITEIT LEIDEN | UNIVERSITE PARIS SORBONNE | UNIVERSITÄT ANTWERPEN | UNIVERSITY COLLEGE LONDON | UNIVERSITY OF COPENHAGEN | UNIVERSITY OF DUNDEE | UNIVERSITY OF GENEVA | UNIVERSITY OF KÖLN | UNIVERSITY OF LANCASTER | UNIVERSITY OF LIVERPOOL | UNIVERSITY OF OXFORD | UNIVERSITY OF PADOVA | UNIVERSITY OF PAVIA | UNIVERSITY OF VERONA | UNIVERSITY OF ZARAGOZA | UPPSALA UNIVERSITET

Projects in the AMR Accelerator:



IMI Associated Partners for ERA4TB



SPONSORED BY THE



IMI Associated Partners for UNITE4TB



www.imi.europa.eu

The AMR Accelerator projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853976 | 853967 | 853979 | 853932 | 853903 | 853800 | 853989 | 101007873 | 101034420. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. ERA4TB has received additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU), EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.